The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.
Melissa L. Johnson, MD, shares key insights from the meeting, including pertinent findings in KRAS G12C¬–mutated NSCLC from the phase 3 CodeBreak 200 study and positive findings with atezolizumab in platinum-ineligible patients with NSCLC.
Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.
Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.
Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share if they believe there should be a standard for molecular testing reports, and how frequently they communicate with their patients during the process.
Lorlatinib improved progression-free survival and reduced 12-month cumulative incidence of central nervous system progression compared with crizotinib in patients with advanced ALK-positive non–small cell lung cancer irrespective of brain metastases at baseline.
Telisotuzumab vedotin in combination with erlotinib induced promising outcomes in patients with advanced, EGFR-mutated, c-MET-positive non–small cell lung cancer who were contraindicated for surgery or other approved therapies.
D. Ross Camidge, MD, PhD, discusses the potential utility of sunvozertinib in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations, the efficacy and safety data observed with the agent, and future research directions.
Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.
Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.
Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.
Sintilimab plus pemetrexed and cisplatin significantly improved progression-free survival vs pemetrexed and cisplatin alone in patients with advanced, EGFR-mutant non–small cell lung cancer who progressed on prior EGFR TKI therapy.
The China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab for use in combination with chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in whom prior treatment with an EGFR TKI has failed.